Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-018-0270-7
Abstract: BackgroundTo our knowledge, inclisiran was the first agent composed of small interfering RNAs (siRNAs) to be preliminarily used to reduce proatherogenic lipoprotein cholesterol levels. Inclisiran was evaluated in large clinical trials but did not receive… read more here.
Keywords: inclisiran 100; randomized controlled; analysis; cholesterol ... See more keywords
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
Sign Up to like & getrecommendations! Published in 2020 at "PharmacoEconomics"
DOI: 10.1007/s40273-020-00948-w
Abstract: Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9). The comparison of inclisiran with statin versus statin alone in the ORION-10 trial demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C). Our study… read more here.
Keywords: analysis; statin; therapy; cardiovascular disease ... See more keywords
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Sign Up to like & getrecommendations! Published in 2022 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehac615
Abstract: Abstract Aims Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascular disease. This study investigates the effect of inclisiran, a small interfering ribonucleic acid targeting hepatic… read more here.
Keywords: day; change; inclisiran; placebo ... See more keywords
Inclisiran patient experiences survey
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Cardiovascular Nursing"
DOI: 10.1093/eurjcn/zvaf122.053
Abstract: Inclisiran is a small interfering ribonucleic acid (siRNA), which increases LDL-C receptor recycling with a projected reduction of 50% in LDL-C. It is a twice a year injectable, licensed in the UK in January 2021.… read more here.
Keywords: primary care; survey; initiation inclisiran; inclisiran ... See more keywords
In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme.
Sign Up to like & getrecommendations! Published in 2024 at "European journal of preventive cardiology"
DOI: 10.1093/eurjpc/zwae254
Abstract: INTRODUCTION Inclisiran, an siRNA targeting hepatic PCSK9 mRNA, administered twice-yearly (after initial and 3-month doses), substantially and sustainably reduced LDL-cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a reduced risk… read more here.
Keywords: sirius programme; trial; silico trial; inclisiran ... See more keywords
Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
Sign Up to like & getrecommendations! Published in 2022 at "Cardiovascular Therapeutics"
DOI: 10.1155/2022/8129513
Abstract: As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal… read more here.
Keywords: targeting pcsk9; disadvantages inclisiran; small interfering; inclisiran ... See more keywords
Abstract 4134364: Predicted Low-Density Lipoprotein Cholesterol and Cardiovascular Outcomes Lowering With Inclisiran in Patients With or Without stroke: Insights from SIRIUS in silico trial.
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4134364
Abstract: Introduction: Inclisiran, an siRNA, targeting PCSK9 mRNA, reduces LDL-c levels. In SIRIUS in silico trial (NCT05974345), inclisiran was predicted to lower cardiovascular (CV) events in virtual patients with atherosclerotic cardiovascular disease (ASCVD). Research question: This… read more here.
Keywords: silico trial; patients without; placebo; inclisiran ... See more keywords
Association of GLP1-RA with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: Biochemical and preclinical evidences.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e24012
Abstract: e24012 Background: Recent meta analyzes have highlighted the key role of oxLDL in cardiovascular risk in patients with/without cancer through the stimulation of pro-inflammatory signaling. GLP-1 receptor agonists, like semaglutide, have shown cardiorenal benefits in… read more here.
Keywords: cancer; therapy; cardiotoxicity; pcsk9i ... See more keywords
PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition
Sign Up to like & getrecommendations! Published in 2025 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms26146617
Abstract: Cardiotoxicity related to anthracyclines and trastuzumab represents a significant clinical challenge in cancer therapy, often limiting treatment efficacy and patient survival. The underlying mechanisms of cardiotoxicity involve the activation of NLRP3 and the MyD88-dependent signaling… read more here.
Keywords: cardiotoxicity; anthracycline; inclisiran; nlrp3 myd88 ... See more keywords
Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
Sign Up to like & getrecommendations! Published in 2024 at "Pharmaceuticals"
DOI: 10.3390/ph17101365
Abstract: Introduction: The discovery of serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9) has revolutionized pharmacological lipid-lowering treatments. The first PCSK9 antagonists (PCSK9-A), evolocumab and alirocumab, were approved in 2015. Targeting PCSK9 synthesis marked a major… read more here.
Keywords: safety inclisiran; inclisiran disproportionality; inclisiran; safety ... See more keywords